These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9166528

  • 21. Oxygen delivery: implications for the biology and therapy of solid tumors.
    Rockwell S.
    Oncol Res; 1997; 9(6-7):383-90. PubMed ID: 9406244
    [Abstract] [Full Text] [Related]

  • 22. [Perspectives in biological modulation of radiotherapy].
    Deutsch E, Huguet F.
    Bull Cancer; 2005 Jan; 92(1):90-6. PubMed ID: 16123013
    [Abstract] [Full Text] [Related]

  • 23. [Biological basis for concomitant chemoradiotherapy in carcinomas].
    Favaudon V, Noël G.
    Bull Cancer; 2005 Dec; 92(12):1027-31. PubMed ID: 16396748
    [Abstract] [Full Text] [Related]

  • 24. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.
    Chen AY, Chou R, Shih SJ, Lau D, Gandara D.
    Crit Rev Oncol Hematol; 2004 May; 50(2):111-9. PubMed ID: 15157660
    [Abstract] [Full Text] [Related]

  • 25. International Clinical Trials in Radiation Oncology. Chemical modifiers.
    Bartelink H, Bleehen NM, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1988 May; 14 Suppl 1():S39-49. PubMed ID: 3292481
    [No Abstract] [Full Text] [Related]

  • 26. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
    Mason KA, Hunter NR, Raju U, Ariga H, Husain A, Valdecanas D, Neal R, Ang KK, Milas L.
    Int J Radiat Oncol Biol Phys; 2004 Jul 15; 59(4):1181-9. PubMed ID: 15234054
    [Abstract] [Full Text] [Related]

  • 27. Radiation sensitization with redox modulators: a promising approach.
    Rosenberg A, Knox S.
    Int J Radiat Oncol Biol Phys; 2006 Feb 01; 64(2):343-54. PubMed ID: 16414370
    [Abstract] [Full Text] [Related]

  • 28. Combining radiation with oxaliplatin: a review of experimental results.
    Hermann RM, Rave-Fränk M, Pradier O.
    Cancer Radiother; 2008 Jan 01; 12(1):61-7. PubMed ID: 18243751
    [Abstract] [Full Text] [Related]

  • 29. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
    De Ridder M, Van Esch G, Engels B, Verovski V, Storme G.
    Bull Cancer; 2008 Mar 01; 95(3):282-91. PubMed ID: 18390408
    [Abstract] [Full Text] [Related]

  • 30. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
    Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz TA, Milas L, Mason KA.
    Clin Cancer Res; 2007 Mar 15; 13(6):1868-74. PubMed ID: 17363543
    [Abstract] [Full Text] [Related]

  • 31. Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets.
    Kvols LK.
    J Nucl Med; 2005 Jan 15; 46 Suppl 1():187S-90S. PubMed ID: 15653668
    [Abstract] [Full Text] [Related]

  • 32. Past, current and future protocols for combined modality therapy in childhood medulloblastoma.
    Kaaijk P, Schouten-van Meeteren AY, Slotman BJ, Kaspers GJ.
    Expert Rev Anticancer Ther; 2003 Feb 15; 3(1):79-90. PubMed ID: 12597352
    [Abstract] [Full Text] [Related]

  • 33. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
    Khuntia D, Mehta M.
    Expert Rev Anticancer Ther; 2004 Dec 15; 4(6):981-9. PubMed ID: 15606327
    [Abstract] [Full Text] [Related]

  • 34. Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines.
    Chen Y, Pandya K, Keng PC, Johnstone D, Li J, Lee YJ, Smudzin T, Okunieff P.
    Clin Cancer Res; 2003 Mar 15; 9(3):969-75. PubMed ID: 12631594
    [Abstract] [Full Text] [Related]

  • 35. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
    King TC, Estalilla OC, Safran H.
    Semin Radiat Oncol; 1999 Apr 15; 9(2 Suppl 1):4-11. PubMed ID: 10210535
    [Abstract] [Full Text] [Related]

  • 36. The role of pentoxifylline as a modifier of radiation therapy.
    Nieder C, Zimmermann FB, Adam M, Molls M.
    Cancer Treat Rev; 2005 Oct 15; 31(6):448-55. PubMed ID: 16225996
    [Abstract] [Full Text] [Related]

  • 37. Targeting molecular determinants of tumor chemo-radioresistance.
    Milas L, Raju U, Liao Z, Ajani J.
    Semin Oncol; 2005 Dec 15; 32(6 Suppl 9):S78-81. PubMed ID: 16399438
    [Abstract] [Full Text] [Related]

  • 38. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
    Rosenthal DI, Nurenberg P, Becerra CR, Frenkel EP, Carbone DP, Lum BL, Miller R, Engel J, Young S, Miles D, Renschler MF.
    Clin Cancer Res; 1999 Apr 15; 5(4):739-45. PubMed ID: 10213207
    [Abstract] [Full Text] [Related]

  • 39. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
    Berry SE, Davis TW, Schupp JE, Hwang HS, de Wind N, Kinsella TJ.
    Cancer Res; 2000 Oct 15; 60(20):5773-80. PubMed ID: 11059773
    [Abstract] [Full Text] [Related]

  • 40. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
    Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3749-55. PubMed ID: 14506167
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.